About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Clinical and Economic Impact of Early Versus Delayed 5-Alpha Reductase Inhibitor Therapy in Men Taking Alpha Blockers for Symptomatic Benign Prostatic Hyperplasia
Patients with prostatic enlargement who had taken an alpha blocker and were then given a 5-alpha reductase inhibitor earlier rather than later had a reduced risk of clinical progression, acute urinary retention, and prostate-related surgery, as well as lower medical costs.
Eric J. Kruep, PharmD, MS; Susan L. Hogue, PharmD, MPH; Michael T. Eaddy, PharmD, PhD; and Monica D. Chandra, MPP
Therapies for melanoma; glioblastoma; non–small-cell lung cancer; gastrointestinal, prostate, and breast cancers; myelofibrosis; and markers for
lymph-node mapping and antibody response
Pharmacy Benefits: Plan Design and Management by F. Randy Vogenberg, PhD, RPh
Reviewed by Joseph E. Biskupiak, PhD, MBA
Continuing Education Credit
Emerging Therapies for Rhythm Control and Stroke Prevention
Non-drug strategies, new antiarrhythmic agents, and anticoagulants all help to
reduce the risk of stroke and provide rhythm control. However, clinicians who
prescribe these therapies must consider the patient’s other illnesses, manage drug interactions, minimize drug toxicity, adjust doses for renal impairment, and provide counseling on the risks of potential adverse effects.
Emily Knapp, PharmD, MBA; and Kristin Watson, PharmD, BCPS
Methadone must be administered with great caution.
Matthew Grissinger, RPh, FASCP
FDA approvals, drug indications, and updates
Medullary thyroid cancer, restless legs syndrome, and preventing kidney transplant rejection
Marvin M. Goldenberg, PhD, RPh, MS
Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia
Lurasidone HCl (Latuda), an oral, atypical antipsychotic agent for schizophrenia
Martin P. Cruz, PharmD, CGP, BCPP